Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges

被引:20
作者
Bernardo, Bianca C. [1 ,2 ,3 ]
Gregorevic, Paul [1 ,4 ]
Ritchie, Rebecca H. [1 ,3 ,5 ]
McMullen, Julie R. [1 ,3 ,6 ,7 ,8 ]
机构
[1] Baker Heart & Diabet Inst, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia
[3] Monash Univ, Dept Diabet, Cent Clin Sch, Clayton, Vic, Australia
[4] Univ Melbourne, Ctr Muscle Res, Dept Physiol, Melbourne, Vic, Australia
[5] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia
[6] Monash Univ, Dept Med, Clayton, Vic, Australia
[7] Monash Univ, Dept Physiol, Clayton, Vic, Australia
[8] La Trobe Univ, Dept Physiol Anat & Microbiol, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
microRNAs; heart failure; tough decoy; microRNA sponge; antisense oligonucleotides; CARDIAC-HYPERTROPHY; THERAPEUTIC INHIBITION; MIRNA THERAPEUTICS; MOUSE MODEL; IN-VIVO; DELIVERY; MICE; NANOPARTICLES; REGENERATION; DYSFUNCTION;
D O I
10.3389/fphar.2018.01090
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Heart failure (HF) is a debilitating and deadly chronic disease, with almost 50% of patients with HF dying within 5 years of diagnosis. With limited effective therapies to treat or cure HF, new therapies are greatly needed. microRNAs (miRNAs) are small non-coding RNA molecules that are powerful regulators of gene expression and play a key role in almost every biological process. Disruptions in miRNA gene expression has been functionally linked to numerous diseases, including cardiovascular disease. Molecular tools for manipulating miRNA activity have been developed, and there is evidence from preclinical studies demonstrating the potential of miRNAs to be therapeutic targets for cardiovascular disease. For clinical application, miRNA sponges and tough decoys have been developed for more stable suppression and targeted delivery of the miRNA of choice. The aim of this study was to generate miRNA sponges and tough decoys to target miR-34 in the mouse heart. We present data to show that using both approaches we were unable to get significant knockdown of miR-34 or regulate miR-34 target genes in the heart in vivo. We also review recent applications of this method in the heart and discuss further considerations for optimisation in construct design and testing, and the obstacles to be overcome before they enter the clinic.
引用
收藏
页数:10
相关论文
共 68 条
[1]   Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma [J].
Babar, Imran A. ;
Cheng, Christopher J. ;
Booth, Carmen J. ;
Liang, Xianping ;
Weidhaas, Joanne B. ;
Saltzman, W. Mark ;
Slack, Frank J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (26) :E1695-E1704
[2]   miRNA sponges: soaking up miRNAs for regulation of gene expression [J].
Bak, Rasmus O. ;
Mikkelsen, Jacob Giehm .
WILEY INTERDISCIPLINARY REVIEWS-RNA, 2014, 5 (03) :317-333
[3]   Managing MicroRNAs with Vector-Encoded Decoy-Type Inhibitors [J].
Bak, Rasmus O. ;
Hollensen, Anne Kruse ;
Mikkelsen, Jacob Giehm .
MOLECULAR THERAPY, 2013, 21 (08) :1478-1485
[4]   miRNAsong: a web-based tool for generation and testing of miRNA sponge constructs in silico [J].
Barta, Tomas ;
Peskova, Lucie ;
Hampl, Ales .
SCIENTIFIC REPORTS, 2016, 6
[5]   Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure [J].
Bass-Stringer, Sebastian ;
Bernardo, Bianca C. ;
May, Clive N. ;
Thomas, Colleen J. ;
Weeks, Kate L. ;
McMullen, Julie R. .
HEART LUNG AND CIRCULATION, 2018, 27 (11) :1285-1300
[6]   Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling [J].
Bernardo, Bianca C. ;
Weeks, Kate L. ;
Pongsukwechkul, Thawin ;
Gao, Xiaoming ;
Kiriazis, Helen ;
Cemerlang, Nelly ;
Boey, Esther J. H. ;
Tham, Yow Keat ;
Johnson, Chad J. ;
Qian, Hongwei ;
Du, Xiao-Jun ;
Gregorevic, Paul ;
McMullen, Julie R. .
CLINICAL SCIENCE, 2018, 132 (03) :381-397
[7]   Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs [J].
Bernardo, Bianca C. ;
Ooi, Jenny Y. Y. ;
Matsumoto, Aya ;
Tham, Yow Keat ;
Singla, Saloni ;
Kiriazis, Helen ;
Patterson, Natalie L. ;
Sadoshima, Junichi ;
Obad, Susanna ;
Lin, Rubyc. Y. ;
McMullen, Julie R. .
JOURNAL OF PHYSIOLOGY-LONDON, 2016, 594 (20) :5959-5974
[8]   Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload [J].
Bernardo, Bianca C. ;
Nguyen, Sally S. ;
Gao, Xiao-Ming ;
Tham, Yow Keat ;
Ooi, Jenny Y. Y. ;
Patterson, Natalie L. ;
Kiriazis, Helen ;
Su, Yidan ;
Thomas, Colleen J. ;
Lin, Ruby C. Y. ;
Du, Xiao-Jun ;
McMullen, Julie R. .
SCIENTIFIC REPORTS, 2016, 6
[9]   miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart [J].
Bernardo, Bianca C. ;
Ooi, Jenny Y. Y. ;
Lin, Ruby C. Y. ;
McMullen, Julie R. .
FUTURE MEDICINAL CHEMISTRY, 2015, 7 (13) :1771-1792
[10]   Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy [J].
Bernardo, Bianca C. ;
Nguyen, Sally S. ;
Winbanks, Catherine E. ;
Gao, Xiao-Ming ;
Boey, Esther J. H. ;
Tham, Yow Keat ;
Kiriazis, Helen ;
Ooi, Jenny Y. Y. ;
Porrello, Enzo R. ;
Igoor, Sindhu ;
Thomas, Colleen J. ;
Gregorevic, Paul ;
Lin, Ruby C. Y. ;
Du, Xiao-Jun ;
McMullen, Julie R. .
FASEB JOURNAL, 2014, 28 (12) :5097-5110